GL1X · GenesisL1 explorer

MolNFT v1 · #92483 · protein

Crystal structure of HLA B2705-KK10

4G9D · HLA class I histocompatibility antigen, B-27 alpha chain: “Crystal structure of HLA B2705-KK10”. X-ray diffraction, 6 pockets (best druggability 0.68). MolNFT v1 #92483 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
4G9D
Type
protein
Length
385 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
HLA class I histocompatibility antigen, B-27 alpha chain; Beta-2-microglobulin; P24
UniProt
P03989, P61769, Q9YXW1
Pockets
6 · best druggability 0.68

Structure

x-ray diffraction · 3 distinct chains · 19% helix, 41% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHLA class I histocompatibility antigen, B-27 alpha chainprotein27627% helix, 39% strandP03989
BBeta-2-microglobulinprotein990% helix, 49% strandP61769
CP24protein100% helix, 0% strandQ9YXW1

Ligands and binding sites

  • GOL · Glycerol · additive · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16600.680.7658GOL
2920.670.9124empty
31140.490.8120empty
4530.410.8216empty
5770.370.7716empty

Interfaces

2 interfaces between chains.

  • A–B · 1310 Ų buried · 21 hydrogen bonds · protein-protein
  • A–C · 950 Ų buried · 21 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 disulfide (disulfide).

Compared structures

  • 4G9D · Crystal Structure of HLA B2705-KK10 · the same entry in another collection · chain B against B, TM-score 1.00
  • P61769 · AlphaFold monomer V2.0 prediction for beta-2-microglobulin (P61769) · a predicted model of the same protein · chain B against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.